Skip to Content
Merck

Key Documents

View All Documentation

S7076

SB 202190 monohydrochloride hydrate

≥98% (HPLC), solid, p38 MAP kinase inhibitor

Synonym(s):

4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole monohydrochloride hydrate, 4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol monohydrochloride hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C20H14FN3O · HCl · xH2O
CAS Number:
350228-36-3
Molecular Weight:
367.80 (anhydrous basis)
UNSPSC Code:
12352200
PubChem Substance ID:
329824576
NACRES:
NA.77
MDL number:
MFCD17215958
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

SB 202190 monohydrochloride hydrate, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

solid

storage condition

desiccated

color

white to beige

solubility

DMSO: ≥12 mg/mL

originator

GlaxoSmithKline

storage temp.

2-8°C

SMILES string

O.Cl.Oc1ccc(cc1)-c2nc(-c3ccc(F)cc3)c([nH]2)-c4ccncc4

InChI

1S/C20H14FN3O.ClH.H2O/c21-16-5-1-13(2-6-16)18-19(14-9-11-22-12-10-14)24-20(23-18)15-3-7-17(25)8-4-15;;/h1-12,25H,(H,23,24);1H;1H2

InChI key

CZZOICWZVYZUNP-UHFFFAOYSA-N

Application

SB 202190 monohydrochloride hydrate has been used as a component of human prostate culture medium and organoid culture medium It has also been used as p38 mitogen activated protein kinase (MAPK) inhibitor in colon cancer cells.
SB 202190 may be used to inhibit p38-mediated cell signaling.

Biochem/physiol Actions

SB 202190 monohydrochloride hydrate mediates the phosphorylation of serine in the mutant p53 protein and modulates cell adhesion and prevents cell proliferation in breast cancer cell lines.
SB 202190 binds within the ATP pocket of p38 kinase and inhibits the p38α and β isoforms.
SB 202190 is a highly selective, potent, and cell-permeable inhibitor of p38 MAP kinase.

Features and Benefits

This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000372088
0000372088
0000481768
0000481766
0000429926

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Organoid culture systems for prostate epithelial and cancer tissue
Drost J, et al.
Nature Protocols, 11(2), 347-347 (2016)
Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration of human MDA-MB-231 cancer cell line
Duzgun SA, et al.
Cytotechnology, 69(4), 711-724 (2017)
Organoid culture of human prostate cancer cell lines LNCaP and C4-2B
Ma L, et al.
American journal of clinical and experimental urology, 5(3), 25-25 (2017)
View All Related Papers